Furthermore, RNA sequencing data revealed that migratory TICs have a gene expression signature distinct from currently used markers in breast cancer (ALDHbr and CD24−/low/CD44+), allowing us to investigate new molecular regulators of TICs. The gene discussed is CD44; the disease is breast carcinoma.